Proactive Investors - Run By Investors For Investors

THC Global Group enters trading halt ahead of permit issue from Office of Drug Control

The halt will remain in place until the start of trading on Friday or when an announcement is released.
THC Global Group enters trading halt ahead of permit issue from Office of Drug Control
THC Global shares last traded at 43 cents each

THC Global Group Ltd (ASX:THC) has been granted a trading halt by the ASX pending an announcement regarding the issue of permits to THC Global’s wholly-owned subsidiary Canndeo Ltd by the Department of Health’s Office of Drug Control.

The halt will remain in place until the earlier of December 21, 2018, or until an announcement is released to market.

READ: THC Global to exclusively import CBD products into New Zealand

THC Global operates under a ‘farm-to-pharma’ pharmaceutical model and is delivering medicinal cannabis products to Australian patients through existing access schemes.

Having secured significant growing capacity over two sites and an industry-leading pharmaceuticals biomanufacturing facility with testing and product development laboratory, THC Global is in prime position to service domestic and international patients.

The company’s commercial partners operate across four continents, supporting future international growth.

READ: THC Global makes move to acquire near-term Canadian cannabis producer

In addition to its core medicinal cannabis business, THC Global owns two Canadian companies, Crystal Mountain Products and Vertical Canna Inc.

Vancouver-based Crystal Mountain operates a revenue-generating global hydroponics retailer and distributor of equipment, material, and nutrients to cannabis growers and producers.

Vertical Canna is an investment vehicle through which THC Global intends to build, through acquisitions and strategic partnerships, a vertically integrated Canadian cannabis producer and retailer.

View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

consumer health segment overview
January 10 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use